Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?

about

Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?

Item

http://www.wikidata.org/entity/Q56893675

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2017

@uk

name

Anti-PD-1 monotherapy versus a ...... ed melanoma: how do we decide?

@en

Anti-PD-1 monotherapy versus a ...... ed melanoma: how do we decide?

@nl

type

Item

label

Anti-PD-1 monotherapy versus a ...... ed melanoma: how do we decide?

@en

Anti-PD-1 monotherapy versus a ...... ed melanoma: how do we decide?

@nl

prefLabel

Anti-PD-1 monotherapy versus a ...... ed melanoma: how do we decide?

@en

Anti-PD-1 monotherapy versus a ...... ed melanoma: how do we decide?

@nl

P1476

Anti-PD-1 monotherapy versus a ...... ed melanoma: how do we decide?

@en

P2093

Aine O'Reilly

http://www.w3.org/2001/XMLSchema#string

James Larkin

http://www.w3.org/2001/XMLSchema#string

Lewis Au

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.

P304

151-155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2217/MMT-2017-0016

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30190919

http://www.w3.org/2001/XMLSchema#string

P932

6094703

http://www.w3.org/2001/XMLSchema#string